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Abstract
It is unknown whether racial differences exist in adjuvant chemotherapy initiation among women 
with similar oncotype DX (ODX) risk scores. We examined whether adjuvant chemotherapy 
initiation varied by race. Data come from the Phase III, Carolina Breast Cancer Study, a 
longitudinal, population-based study of North Carolina women diagnosed with breast cancer 
between 2008 and 2014. We used modified Poisson regression and report adjusted relative risk 
(aRR) and 95 % confidence intervals (95 %CI) to estimate the association between race and 
adjuvant chemotherapy initiation across ODX risk groups among women who received the test (n 
= 541). Among women who underwent ODX testing, 54.2, 37.5, and 8.3 % of women had tumors 
classified as low-, intermediate-, and high-risk groups, respectively. We observed no racial 
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variation in adjuvant chemotherapy initiation. Increasing ODX risk score (aRR = 1.39, 95 %CI = 
1.22, 1.58) and being married (aRR = 2.92, 95 %CI = 1.12, 7.60) were independently associated 
with an increased likelihood of adjuvant chemotherapy in the low-risk group. Among women in 
the intermediate-risk group, ODX risk score (aRR = 1.15, 95 %CI = 1.11, 1.20), younger age (aRR 
= 1.95, 95 %CI = 1.35, 2.81), larger tumor size (aRR = 1.70, 95 %CI = 1.22, 2.35), and higher 
income were independently associated with increased likelihood of adjuvant chemotherapy 
initiation. No racial differences were found in adjuvant chemotherapy initiation among women 
receiving ODX testing. As treatment decision-making becomes increasingly targeted with the use 
of genetic technologies, these results provide evidence that test results may drive treatment in a 
similar way across racial subgroups.
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Background
Black women are less likely to develop, but more likely to die from, breast cancer than non-
Black women [1]. This disparity likely arises from a complex array of biological, societal, 
and health system factors, including access to high-quality cancer care [2]. For example, 
Black women with breast cancer are less likely to receive guideline-concordant cancer 
treatment, with mixed evidence about adjuvant chemotherapy [3, 4] and endocrine therapy 
initiation and adherence [5]. While the vast majority of women with node-negative, 
hormone receptor-positive breast cancer are recommended to take endocrine therapy to 
reduce 10-year risk of recurrence, only about 15 % of these women are thought to reap 
added benefit from adjuvant chemotherapy in addition to endocrine therapy [6].
In 2004, Oncotype DX (ODX) (Genomic Health, Redwood City, CA) became commercially 
available as a tool for identifying which women with early-stage, estrogen receptor-positive 
(ER+) breast cancer are likely to benefit from adjuvant chemotherapy. ODX is a 21-tumor 
gene expression profiling panel that not only predicts 10-year distant recurrence, but also 
estimates the benefit of adjuvant chemotherapy [6, 7]. The test categorizes women as being 
at “low,” “intermediate,” or “high” risk of recurrence; low-risk women are predicted to 
derive no significant benefit from adjuvant chemotherapy, while high-risk women appear to 
have improved recurrence-free survival if they receive adjuvant chemotherapy in addition to 
endocrine therapy. Thus current guidelines recommend that women with low-ODX risk 
scores forgo adjuvant chemotherapy and that women with high-risk scores have adjuvant 
chemotherapy [8]. Within the intermediate group, there is less certainty regarding the benefit 
of adjuvant chemotherapy in terms of 10-year distant recurrence; instead adjuvant 
chemotherapy decision-making can be tailored to individual patients.
ODX has the potential to decrease racial disparities in treatment—especially among women 
in the low- and high-risk groups—because it provides an evidence-based tool to guide 
decisions. Alternatively, ODX testing could exacerbate treatment disparities if minority 
women have lower access to the test (and therefore fewer opportunities for informed 
decisions). To date, little is known about adjuvant chemotherapy decision-making in the 
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presence of ODX risk information in a population-based study. The only published study to 
examine this question did not find racial disparities in the use of adjuvant chemotherapy 
among women with ODX; however findings may not be generalizable, as it was conducted 
within three urban, academic-affiliated hospitals [9].
Using a large, registry-based prospective cohort study, we examined racial disparities in 
adjuvant chemotherapy initiation among women receiving ODX. We described racial 
differences in ODX risk scores and elucidated whether adjuvant chemotherapy initiation 
varies by race within (1) the low- and high-risk groups, with clear guidelines for adjuvant 
chemotherapy use, and (2) the intermediate group, where the treatment decision in response 
to ODX results is less clear.
Methods
Data source
We used Carolina Breast Cancer Study, Phase III (CBCS-III) data (NCI-P50-CA58223). 
CBCS-III is a prospective cohort study of 2998 women with invasive breast cancer across 
44 counties in North Carolina (NC). In collaboration with the NC Cancer Registry, women 
were enrolled using rapid case ascertainment. Notably, CBCS-III oversamples young and 
Black women, making it ideally suited for examining racial differences in breast cancer care. 
Between 2008 and 2013, patients were randomly sampled from four strata: Black women 
<50 years, Black women ≥50 years, non-Black women <50 years, and non-Black women 
≥50 years [10]. For this study, we used data from baseline surveys, medical record 
abstractions, and pathology reports.
Sample
Inclusion criteria for this study included women with a single breast tumor that was ER+, 
stage I–II, HER2 negative, and who had ODX test results; we excluded women with 
undetermined tumor grade or missing data on tumor size, PR status, employment status or 
family income (Appendix 1 in ESM). Our final sample included 186 Black and 355 non-
Black women.
Measures
Dependent variable—Our primary outcome was adjuvant chemotherapy initiation, 
defined as initiation following the primary surgery as determined from medical records.
Independent variable—Race was self-reported. We dichotomized race as non-Black 
(93.5 % White, 2.3 % Asian, and 4.2 % other) or Black, irrespective of ethnicity.
Covariates—Covariates included clinical (comorbidities, age at diagnosis), tumor (size, 
grade, ODX risk score, node status), treatment (lumpectomy/mastectomy), and 
socioeconomic characteristics. Age at diagnosis was dichotomized (<50 versus ≥50 years). 
We calculated the number of comorbidities recorded in patient medical records. We 
considered five comorbidities that are clinically likely to affect adjuvant chemotherapy 
decision-making: heart disease, hypertension, obesity, diabetes, and chronic obstructive 
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pulmonary disease. Tumor and treatment characteristics were abstracted from the pathology 
and medical reports, respectively. Socioeconomic variables included marital status (married, 
living as married/other), education (less than high school/high school/college and more), 
current employment since diagnosis (yes/no), annual family income (<$15,000/$15,000–
30,000/$30,000–50,000/>$50,000), and insurance type (insured/uninsured).
Analyses
Descriptive analyses used weighted linear regression for continuous variables and weighted 
Chi square tests for categorical variables. We compared the distribution of ODX risk scores 
in the sample overall and by race. We also graphed the kernel density of ODX risk scores by 
race. We compared sample characteristics by race and adjuvant chemotherapy initiation. Per 
our data-use agreement, data were not reported for cell sizes with <5 observations. Our 
primary analysis employed a modified Poisson regression to examine the association 
between race and adjuvant chemotherapy initiation. Modified Poisson regression estimates 
relative risk consistently and efficiently with binary outcomes, using sandwich standard 
errors [11, 12]. We addressed complex survey design through sample weights and design 
effects using Taylor series approximations. We accounted for clustered standard errors at the 
provider-level, and we conducted a complete case analysis (missing data, n = 37).
We used the Institute of Medicine (IOM) definition of health disparity to guide covariate 
inclusion. Specifically, the IOM model for disparities implies that race is a social construct 
[13, 14]. Thus, we did not include socioeconomic variables (marital status, education, 
current employment, family income, and insurance type) in our primary model, which 
measured the reduced form effect of race on adjuvant chemotherapy use. To examine the 
residual direct effect of race on adjuvant chemotherapy use, we also estimated a secondary 
model, including socioeconomic covariates.
A priori, we specified that we would stratify analyses by ODX risk category: low (risk 
score<18), intermediate (risk score 18–30), high (risk score >30), because the evidence-
based guidelines for adjuvant chemotherapy differ across ODX risk groups. Because so few 
women in the sample were categorized with high-ODX scores, we lacked sufficient power 
to examine multivariate relationships between race and adjuvant chemotherapy initiation. 
Thus, we only present unadjusted racial differences in this group. Finally, we present six 
models including unadjusted, primary, and secondary models within low- and intermediate-
risk group strata. Analyses were conducted using STATA (Stata-Corps, College Station, TX, 
USA). This research was approved by the University of North Carolina Institutional Review 
Board.
Results
Racial differences in ODX risk score
Overall, 54.2 % of women were in the low-, 37.5 % in the intermediate-, and 8.3 % in the 
high-risk groups (Table 1). There were no racial differences in the proportion of non-Black 
compared to Black women in the low-, intermediate-, and high-ODX risk groups (Table 1). 
Within ODX risk groups, mean ODX risk scores were similar among non-Black and Black 
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women in the high- (41.6, 39.6, p = 0.85) and low-risk groups (11.2, 11.3, p = 0.42); 
however, Black women had a somewhat higher mean risk score within the intermediate-
ODX risk group than non-Black women (23.5, 22.3, p = 0.04) (Table 1; Fig. 1).
Within the low- and high-risk groups, tumor characteristics by race were similar; except in 
the low-risk group where Black women were more likely to have higher tumor grade than 
non-Black women (Table 1). In the intermediate-risk group, Black women had higher ODX 
scores and were more likely to have progesterone receptor-negative breast cancer than non-
Black women. Treatment characteristics were similar between Black and non-Black women 
within all ODX risk groups. Comorbidities, especially diabetes and hypertension, were 
higher in Black than non-Black women across risk groups. Age at diagnosis was similar 
across racial groups in all risk groups; however Black women were slightly younger at 
diagnosis than non-Black in the low-risk group. Socioeconomic characteristics were lower 
among Black women than non-Black women regardless of risk group (Table 1).
In bivariate analyses, women who initiated chemotherapy had higher ODX risk scores, 
larger tumors, higher tumor grade, younger age at diagnosis, less heart disease and COPD, 
and less likely to have Medicare (Table 2). Among those with low-risk ODX scores, only 
6.1 % received adjuvant chemotherapy. Conversely, among women with high-risk scores, 
80.1 % initiated chemotherapy, given evidence-based recommendations to do so. In the 
intermediate-risk group, (45.7 %) of patients started chemotherapy (Table 2).
Racial differences in adjuvant chemotherapy initiation in risk groups: higher treatment 
certainty in guidelines
Low-risk group—No association between race and adjuvant chemotherapy uptake was 
observed within the low-risk group (Table 3; Appendix 2 in ESM). In this group, holding 
other factors constant, higher ODX scores were associated with an increased likelihood of 
chemotherapy initiation in both the primary and secondary models (primary aRR 1.35, 95 
%CI = 1.17–1.55, p < 0.001; secondary aRR 1.39, 95 %CI = 1.22–1.58, p < 0.001). In the 
secondary model, being married was also independently associated with an increased 
likelihood of adjuvant chemotherapy uptake (secondary aRR 2.92, 95 %CI = 1.12–7.60, p < 
0.028). Finally, having high- versus low-grade tumors (secondary aRR 3.57, 95 %CI = 1.08–
11.76, p = 0.037) and having larger tumor size (secondary aRR 3.45, 95 %CI = 1.28–9.29, p 
= 0.014) were each independently associated with an increased likelihood of adjuvant 
chemotherapy initiation in the secondary model.
High-risk group—No racial differences were found in adjuvant chemotherapy initiation 
among women in the high-risk group, though a non-significant increased likelihood of 
chemotherapy was found among Black women (unadjusted RR = 1.24, 95 % CI = 0.94–
1.62, p = 0.12) (Appendix 2 in ESM). Small sample size precluded our ability to explore 
beyond the unadjusted model.
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Racial differences in adjuvant chemotherapy initiation in the intermediate-risk group: 
lower treatment certainty in guidelines
No racial differences in adjuvant chemotherapy initiation were observed; however, several 
other factors independently associated with increased risk of chemotherapy initiation 
included (Table 3; Appendix 2 in ESM) higher ODX score (primary aRR = 1.15, 95 %CI = 
1.11–1.19, p < 0.001; secondary aRR = 1.15, 95 %CI = 1.11–1.20, p < 0.001), younger age 
(primary aRR = 2.00, 95 %CI = 1.39–2.89, p < 0.001; secondary aRR = 1.95, 95 %CI = 
1.35–2.81, p < 0.001), and tumor size ≥2 cm (primary aRR = 1.51, 95 %CI = 1.12–2.035, p 
= 0.007; secondary aRR = 1.70, 95 %CI = 1.22–2.35, p = 0.002). Being diagnosed in 2012 
or 2013 was associated with lower risk of adjuvant chemotherapy initiation (primary aRR = 
0.56, 95 %CI = 0.33–0.97, p < 0.037; secondary aRR = 0.54, 95 %CI = 0.30–0.96, p = 
0.036). In the secondary model, the lowest income patients were independently more likely 
to initiate chemotherapy than patients with higher incomes.
Discussion
Overall, we found no racial disparities in adjuvant chemotherapy initiation across ODX risk 
groups, nor did we observe racial differences in mean ODX risk scores within the high- and 
low-risk groups. In the intermediate-risk group, Black women had slightly higher ODX risk 
scores than non-Black women. However, the magnitude of this difference was small, and 
likely not clinically meaningful, corroborating a previous study that reported no significant 
racial differences in mean ODX risk scores [9]. Unlike that study, we did not observe 
significant racial differences in the distribution of women into ODX risk groups [9].
In our study, only 8 % of women were classified with high-risk scores. This differs 
significantly from preliminary ODX validation studies, where 27 % of women with early-
stage breast cancer were classified as high risk [6]. Notably, subsequent observational 
studies have found the proportion of high-risk scores to be similar to what we observed [9]. 
In a qualitative study, providers discussed being less likely to order ODX testing for more 
aggressive tumors, because they felt that they already had the necessary information to offer 
adjuvant chemotherapy [15]. This may explain why women with high-risk scores are less 
likely to receive ODX testing in real-world practices.
We did not find racial disparities in adjuvant chemotherapy initiation. There are several 
plausible explanations for this finding. First, we examined women with early-stage, ER+, 
HER2− breast cancer who received ODX testing. These women may already have had 
access to high-quality breast cancer care that would attenuate racial differences in 
chemotherapy initiation. Second, it is possible that ODX information mediates variation in 
the uptake of adjuvant chemotherapy by providing an objective tool to guide treatment 
decision-making. Third, the nonsignificant association between race and adjuvant 
chemotherapy initiation may result from small sample size, especially in multivariate 
models. Finally, studies of racial variation in breast cancer care have not consistently 
demonstrated racial disparities in adjuvant chemotherapy initiation. While some studies 
report underuse of adjuvant chemotherapy among minority and low-income women [3, 4, 
16], others do not [17–19]. Furthermore, some studies suggest that racial disparities in 
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adjuvant chemotherapy use occur not in initiation, but rather in delays [20–22], which was 
not evaluated in our study.
Despite guideline recommendations to forgo chemotherapy for low-ODX risk tumors, 6.1 % 
of women still initiated adjuvant chemotherapy. Within the low-risk group, higher ODX 
score was associated with an increased likelihood of chemotherapy initiation. This may 
reflect that ODX scores are being used along a continuum; if so, within risk groups, 
physicians may perceive some women to be at higher risk than others. In our secondary 
model, larger tumor size and higher tumor grade were each independently associated with 
increased risk of chemotherapy initiation, suggesting that such tumor characteristics play a 
role in adjuvant chemotherapy initiation, even in the presence of a low-ODX risk score. 
Finally, consistent with previous literature, being married was associated with an increased 
likelihood of chemotherapy initiation among women in the low-risk group, possibly due to 
more social support and resources to pursue additional treatments [23].
Interestingly, 19.9 % of patients in the high-risk group failed to initiate adjuvant 
chemotherapy despite guidelines. Small sample size limited our ability to investigate factors 
associated with adjuvant chemotherapy receipt in this group. Qualitative analyses suggest 
that women who forgo chemotherapy in this group typically do so because of patient 
preferences [15].
Within the intermediate group, almost half of women received chemotherapy. Race did not 
influence chemotherapy initiation; however, similar to the low-risk group, higher ODX 
score and larger tumors were associated with adjuvant chemotherapy initiation. Taken 
together, tumor characteristics appeared to play a major role in directing adjuvant 
chemotherapy decision-making within the intermediate-risk group. Younger age was also 
associated with higher risk of adjuvant chemotherapy initiation, which is consistent with 
studies demonstrating that younger women receive more aggressive treatment [15, 24]. This 
may be explained by better overall health, tolerability of adjuvant treatment, more 
aggressive tumors, or patient preferences. Interestingly, having an annual family income 
below $15,000 was associated with a higher likelihood of adjuvant chemotherapy initiation, 
potentially due to differential patient preferences or provider-level prescribing patterns. 
Finally, being diagnosed with breast cancer in 2012 or 2013 was associated with a lower 
likelihood of adjuvant chemotherapy use, perhaps indicating a change in practice patterns 
over time.
This study has several limitations. First, while CBCS-III is a large, longitudinal breast 
cancer cohort that oversamples Black women, we were underpowered to fully explore racial 
disparities in multivariable models, particularly in the high-risk group. Second, we were 
unable to account for patient preferences, which likely play a role in ordering ODX testing 
and adjuvant chemotherapy decision-making [25]. Third, we lacked data on organizational 
and provider characteristics that influence adjuvant chemotherapy use [9, 26, 27]. Moving 
forward, it may be possible to link organizational- and provider-level data to the CBCS-III 
dataset, facilitating such analyses. Finally, we conducted a complete case analysis under the 
assumption that data were missing at random. If this assumption is violated, then estimates 
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may be biased. However, we did not observe significant differences by race, ODX risk 
score, or chemotherapy initiation between women with and without missing data.
Our study adds to the literature by investigating the uptake of adjuvant chemotherapy among 
women receiving ODX testing by race within a large prospective, population-based cohort 
study of breast cancer patients. Our findings suggest that racial disparities in adjuvant 
chemotherapy use do not exist among breast cancer patients receiving ODX testing. This is 
heartening, as more genetic technologies are incorporated into treatment decision-making. 
Future research should consider potential disparities at the point of access and incorporate 
organizational-, provider-, and patient-level data into studies that seek to understand racial 
variation in oncology treatment decision-making.
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Distribution of ODX risk scores by race, with reference lines indicating cut off points (at 18 
and 30 scores) for the low-, intermediate-, and high-risk groups [6]
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Table 1
Patient characteristics by race and ODX risk group
n (weighted proportion) ODX risk group
Mean (standard deviation) or %

















(12.3 %) p 
†
Tumor characteristics
    ODX recurrence score 11.2 (3.9) 11.3 (6.6) 0.85 22.3 (3.2) 23.5 (5.9) 0.04 41.6 (7.2) 39.6 (13.1) 0.42
    AJCC Stage 1 (v. 2) 68.3 66.5 0.79 62.5 67.8 0.47 77.9 51.6 0.08
    Tumor size category 0.64 0.60 0.16
        <2 cm 75.3 72.3 70.8 74.1 77.9 57.0
        2+ cm 24.7 27.7 29.2 25.9 22.1 43.0
    Combined grade 0.03 0.39 0.29
        1 42.3 26.3 23.1 32.2 * *
        2 53.2 65.2 57.8 54.2 * 25.8
        3 4.5 8.5 19.1 13.6 79.9 68.8
    PR positive 96.7 97.3 0.79 89.9 72.7 0.003 67.8 55.9 0.44
Treatment characteristics
    Chemo initiation 5.9 7.2 0.69 46.2 42.7 0.66 76.5 94.6 0.11
    ET initiation 92.4 93.1 0.84 97 94.4 0.41 92.6 84.9 0.42
    Radiation initiation 67.4 70.2 0.68 66.9 70.6 0.62 57 59.1 0.89
    Lumpectomy (v. mastectomy) 66.3 66.5 0.98 63.5 71.7 0.27 57 62.4 0.74
Clinical characteristics
    Age at diagnosis 57.4 (8.7) 54.4 (15.6) 0.002 56.4 (8.7) 55.8 (15.7) 0.66 57.7 (9.8) 55.4 (17.3) 0.22
    #Comorbidities 0.7 (0.8) 1.1 (1.5) <0.001 0.5 (0.6) 1.0 (1.4) <0.001 0.7 (1.0) 1.4 (1.2) 0.02
        Diabetes 7.4 20.7 0.003 7.7 20.3 0.01 * 40.9 0.01
        COPD * * 0.62 * * 0.56 * * 0.59
        Obesity 14 21.3 0.13 8.7 18.2 0.1 * 31.2 0.07
        Heart disease 4.8 * 0.19 * * 0.3 * * >0.99
        Hypertension 39.8 64.9 <0.001 31.1 59.4 <0.001 43.6 66.7 0.08
Socioeconomic factors
    Annual family income <0.001 <0.001 0.02
        <$15K 7.6 18.9 4.4 17.5 * *
        $15-30K 12.2 24.7 6.5 30.1 23.5 32.3
        $30-50K 18.1 23.4 16.3 26.9 19.5 *
        >$50K 62.0 33.0 72.8 25.5 57 37.6
    Insurance
        Private 80.7 69.3 0.05 85.7 66 0.01 67.8 77.6 0.47
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n (weighted proportion) ODX risk group
Mean (standard deviation) or %

















(12.3 %) p 
†
        Medicaid 5.6 19.3 <0.001 4 19.3 <0.001 * 22.4 0.14
        Medicare 32.5 24.4 0.19 31 28.2 0.73 43 42.4 0.97
        Uninsured * 10.6 <0.001 3 9.4 0.07 * * 0.01
    Married 69.5 46.8 <0.001 82.2 43.7 <0.001 68.5 31.2 0.02
    Employed 49.8 51.3 0.81 53.7 43.7 0.19 41.6 40.9 0.96
    Education 0.008 0.1 0.81
        HS & Post-HS 47.8 48.1 46.9 59.8 51.7 48.4
        College+ 49.4 39.6 47.9 31.1 37.6 34.4
        <HS 2.8 12.2 5.3 9.1 * *
Year of diagnosis
0.16 0.30 0.80
    2008 6.1 13.6 15.4 9.1 23.5 *
    2009 19.2 20.2 20.3 17.5 * *
    2010 27.3 17.8 20.1 24.8 27.5 22.6
    2011 25.2 28.5 20.7 31.5 22.1 37.6
    2012/2013 22.2 19.9 23.5 17.1 * *
*
Data not reported for cell sizes <5
†
p value for weighted χ2 = 0.23. Because of small cell size, we combined women who were diagnosed in 2013 (n = 8) with 2012, and women who 
had tumor size >5 cm (n = 5) with 2-5 cm













Roberts et al. Page 13
Table 2
Sample characteristics by adjuvant chemotherapy initiation
n Mean (SD) or %
No. chemotherapy 373 Chemotherapy 168 p
Tumor characteristics
    ODX recurrence score 14.4 (6.6) 27.6 (11.4) <0.001
    ODX risk group
        Low 93.9 6.1 <0.001
        Intermediate 54.3 45.7
        High 19.9 80.1
        <2 cm tumor size (vs. 2 cm+) 76.9 64.2 0.01
    Combined grade <0.001
        1 36.8 18.3
        2 55.2 44
        3 8 37.7
    PR positive 92.3 86.4 0.06
Treatment characteristics
    ET initiation 93.1 96.1 0.25
    Radiation initiation 68.4 62.4 0.24
    Lumpectomy 65 68 0.03
Clinical characteristics
    Age at diagnosis 58.0 (9.4) 53.6 (11.3) <0.001
    # Comorbidities 0.7 (0.9) 0.6 (0.9) 0.40
        Diabetes 9.4 10.3 0.78
        COPD 2.5 a 0.12
        Obesity 12.7 13.2 0.87
        Heart disease 4.5 a 0.001
        Hypertension 40.9 38.9 0.7
Socioeconomic characteristics
    Annual family income 0.98
        <15K 7.6 7.2
        15-30K 13.3 13.0
        30-50K 18.8 17.4
        >50K 60.4 62.4
    Insurance
        Private 79.2 82 0.55
        Medicaid 6.2 8.5 0.41
        Medicare 35.2 23.9 0.05
        Uninsured 2.6 4.0 0.41
    Married 69.8 70.7 0.85
    Employed 49.7 51.3 0.78
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n Mean (SD) or %
No. chemotherapy 373 Chemotherapy 168 p
    Education 0.93
        HS & Post-HS 48.5 48.3
        College+ 46.5 45.7
        <HS 5.1 6.0
Year of diagnosis
    Year 0.07
        2008 8.5 18.1
        2009 19.8 17.1
        2010 25.4 20.7
        2011 23.4 26.8
        2012/2013 23.0 17.2
a
Data not reported for cell sizes <5. We combined women who were diagnosed in 2013 (n = 8) with 2012, and women who had tumor size >5cm 
(n = 5) with 2-5 cm
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